# Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

> **NCT05425745** · PHASE3 · COMPLETED · sponsor: **NewAmsterdam Pharma** · enrollment: 354 (actual)

## Conditions studied

- Dyslipidemias
- High Cholesterol
- Hypercholesterolemia
- Familial Hypercholesterolemia
- Lipid Metabolism Disorder
- Metabolic Disease
- Lipid Metabolism, Inborn Errors
- Genetic Disease, Inborn
- Hyperlipoproteinemias

## Interventions

- **DRUG:** Obicetrapib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05425745
- **Lead sponsor:** NewAmsterdam Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-25
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05425745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05425745, "Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05425745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*